Method for producing exosome-containing liquid derived from mesenchymal stem cells, and pharmaceutical product containing exosome-containing liquid
The described method efficiently extracts exosomes from mesenchymal stem cells using freeze-thaw and filtration, addressing inefficiencies and risks in existing technologies, enabling safe and cost-effective production for therapeutic and cosmetic uses.
Patent Information
- Application Number
- SA1120262020
- Authority / Receiving Office
- SA · SA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-06-01
- Filing Date
- 2026-03-11
- Publication Date
- 2026-10-06
AI Technical Summary
Existing methods for extracting and utilizing exosomes from mesenchymal stem cells are inefficient, costly, and pose risks such as carcinogenesis and transplant rejection due to the presence of live cells.
A method involving freeze-thaw treatment, stirring, and filtration is used to extract exosomes from mesenchymal stem cells, eliminating live cells and reducing the need for expensive equipment, allowing for high-concentration exosome production.
The method produces a high-concentration exosome solution suitable for therapeutic and cosmetic applications, with reduced risks and costs, and enables long-term storage and safe administration.
Smart Images

Figure 9823C27C-C74A-4649-ACD2-471F0CD9BFF6
Abstract
Description
Exosomes: In the context of the present invention, an "exosome" is defined as an endoplasmic reticulum consisting of a lipid bilayer, which is secreted from the cell to the outside. The lipid bilayer membrane contains proteins, lipids, nucleic acids (such as miRNA, mRNA, DNA, and the like), and other substances. Exosomes are endoplasmic networks that secrete from cells to the outside. Exosome formation begins with the formation of an early endosome via endocytosis, involving receptors located in the cell membrane. The early endosome then transforms into a late endosome, which folds inwards to form intramembrane vesicles (ILVs). Finally, the endosome (a multivesicle body (MVB) containing numerous ILVs) fuses with the cell membrane, and the ILVs are released from the cell. The inventors of the current invention focused on the mesenchymal stem cells themselves that secrete exosomes, and succeeded in extracting the exosomes present inside the cells before they are secreted, in addition to the exosomes that are secreted when the cells are disrupted. mesenchymal stem cells In the present invention, the exosome-secreting mesenchymal stem cell is a cell belonging to the mesenchymal system, known for its pluripotency and ability to self-replicate, and has the ability to differentiate into connective tissue cells such as bone cells, cartilage cells, and fat cells, as well as into nerve cells and heart muscle cells. Examples of tissues containing mesenchymal stem cells include adipose tissue, umbilical cord, bone marrow, umbilical cord blood, endometrium, placenta, amniotic membrane, chorionic membrane, decidua, dermis, skeletal muscle, periosteum, dental follicle, periodontal ligament, dental pulp, and tooth germ. Of these, mesenchymal stem cells derived from adipose tissue, umbilical cord blood, bone marrow, or dental pulp are preferred. Among these, adipose-derived mesenchymal stem cells are preferred due to their ease of collection. Adipose tissue-derived mesenchymal stem cells, cord blood-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and dental pulp-derived mesenchymal stem cells are prepared according to a well-known traditional method. Here, the method for preparing adipose tissue-derived mesenchymal stem cells will be described, as they are the preferred cells, specifically. The biological origin of the mesenchymal stem cells in the present invention is not specifically limited, but includes non-human mammals (including domestic animals, livestock, and laboratory animals, for example, monkeys, pigs, cows, horses, goats, sheep, dogs, cats, camels, mice, rats, guinea pigs, and hamsters), as well as humans. When the exosome solution in the invention is used as a medicinal preparation, it is preferable to collect mesenchymal stem cells from the same recipient (autologous). However, the use of mesenchymal stem cells from the same animal species (allogeneic) or from a different animal species is not prohibited. adipose tissue-derived mesenchymal stem cells Adipogenic mesenchymal stem cells (ADSCs, also known as fat-derived stem cells, ASCs, ADRCs, AT-MSCs, AD-MSCs, or similar names; hereafter simply as ADSCs) are a type of somatic stem cell found in adipose tissue. ADSCs are also characterized by their ability to self-renew and multiply, and are known for their capacity to differentiate not only into adipocytes but also into various cell types such as osteoblasts, chondrocytes, neurons, muscle cells, cardiomyocytes, vascular cells, hepatocytes, and pancreatic islet cells. Method of preparing mesenchymal stem cells derived from adipose tissue In the present invention, as long as the ADSCs retain their pluripotency, cells obtained by culture (including subculture) of somatic stem cells are also considered ADSCs. Typically, ADSCs are prepared in an "isolated state" as cell-forming cells (including cells other than ADSCs derived from adipose tissue) using adipose tissue isolated from a living organism as the starting material. Here, "isolated state" refers to the state in which the cell is taken from its original environment (i.e., a state representing a part of a living organism), i.e., the state in which the cell exists in an environment different from its original state as a result of an artificial process. The ADSCs used in this invention must be prepared according to a well-established conventional method. ADSCs are widely used in various applications, and therefore, specialists in the field can prepare them by referring to the relevant literature and scientific documents. Distributed cells from a public cell bank, commercially available cells, or similar sources may also be used. As an example of cell preparation, the preparation of adipose tissue-derived mesenchymal stem cells (as one example) will be described below. ADSCs are prepared through steps such as isolation, washing, concentration, and cell culture from adipose matrix. The method for preparing ADSCs is not particularly limited. For example, ADSCs can be prepared using well-known methods (see: Fraser JK et al. (2006), Fat tissue: an underappreciated source of stem cells for biotechnology. Trends in Biotechnology; Apr; 24 (4): 150-4. Epub 2006 Feb 20. Review.; Zuk PA et al. (2002), Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell; Dec; 13 (12): 4279-95.; Zuk PA et al. (2001), Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering; Apr; 7 (2): 211-28; and similar sources). In addition, commercially available devices for preparing ADSCs from adipose tissue (e.g., the Celution® device from Cytori Therapeutics, Inc., San Diego, USA) are available, and ADSCs can be prepared using these devices. When using these devices, a cell pool containing ADSCs can be isolated from the adipose tissue (K. Lin et al. Cytotherapy (2008) Vol. 10, No. 4, 417-426).Below, a specific example of how ADSCs are prepared will be described. Preparation of the cell cluster from adipose tissue Adipose tissue is collected from humans and non-human mammals by methods such as excision and liposuction. Non-human mammals can be any animal, provided it falls within the categories previously mentioned, and may include pets, livestock, or laboratory animals. Furthermore, the selection is not limited by the age or sex of the organism. In the case of humans, ADSCs can also be prepared from tissue samples extracted via liposuction during cosmetic procedures, or from adipose tissue removed from the organism's body during surgery or similar procedures. ADSCs are located around large blood vessels and are therefore more readily obtained from adipose tissue than from liposuction fluid. When preparing stem cells from liposuction fluid, the surgical scarring is minimal, and the burden on the donor is reduced. Examples of adipose tissue include subcutaneous fat, visceral fat, intramuscular fat, and intermuscular fat. Of these, subcutaneous fat is most easily collected under local anesthesia, thus reducing the burden on the donor during collection and making it a preferred cell source. Typically, only one type of adipose tissue is used, but two or more types can be combined. Furthermore, the collected adipose tissue can be mixed multiple times (and does not necessarily have to be of the same type) and used for subsequent procedures. The amount of adipose tissue collected can be determined based on the donor type, tissue type, or the required number of ADSCs, and is typically around 0.5 to 500 grams. However, considering the donor's burden, it is preferable to collect approximately 3 to 20 grams or less at a time. After collection, the adipose tissue undergoes enzymatic processing after the removal of any adhering blood components and is sectioned as needed. Blood components can be removed by washing the adipose tissue in a suitable buffer solution or culture solution. Enzyme therapy is performed by digesting adipose tissue using an enzyme such as collagenase, trypsin, or dyspeps. It is sufficient for enzyme therapy to be carried out according to methods and conditions familiar to specialists in the field (see: R.I. Freshney, Culture of Animal Cells: A Manual of Basic Technique, 4th ed., John Wiley & Sons Inc.). The resulting cell pool from enzyme therapy includes, for example, pluripotent stem cells, endothelial cells, supporting tissue cells, blood cells, and their progenitor cells. The type and proportion of cells that make up the cell pool depend on the origin and type of adipose tissue used. (2) Obtaining precipitated cell aggregates (SVF fractions: vascular stromal fractions) The cell pool is then subjected to centrifugation. The resulting precipitate is collected as a precipitated cell pool (hereafter also referred to as "SVF fraction"). Centrifugation conditions vary depending on the cell type and quantity, and are, for example, 1 to 10 minutes at a speed of 800 to 1,500 rpm. Prior to centrifugation, it is preferable to filter the enzyme-treated cell pool or perform a similar process to remove any undigested tissue and other constituents. The SVF fraction obtained here includes adipocyte subunits (ADSCs). The type, proportion, and other characteristics of the cells that make up the SVF fraction depend on the origin and type of adipose tissue used, the enzyme treatment conditions, and other factors. Furthermore, international patent publication WO2006 / 006692 A1 details the properties of the SVF fraction. Selective culture of adhesion cells (ADSCs) and cell collection The SVF fraction includes other cellular components (such as endothelial cells, stromal cells, blood cells, their progenitor cells, and the like) in addition to ADSCs. Therefore, in one embodiment of the present invention, the following selective culture is performed to remove the unnecessary cellular components from the SVF fraction. The cells obtained in this way are then used in the present invention as ADSCs. Initially, the SVF fraction is suspended in a suitable culture medium, then cultured on a culture dish, and cultured overnight. Floating cells (non-adherent cells) are removed by replacing the medium. Subsequently, culture is continued with appropriate medium replacements (e.g., every 2 to 4 days). Where necessary, secondary culture is performed. The number of fragments is not specified; however, from the perspective of preserving pluripotency and reproducibility, excessive fragment duplication is not desirable (and it is preferable to keep the number of fragments to approximately 6). As for the culture medium, a normal culture medium can be used for culturing animal cells.For example, Dulbecco's Modified Eagle's Medium (DMEM) (e.g., NISSUI PHARMACEUTICAL CO., LTD.), α-MEM (e.g., Dainippon Pharmaceutical Co., Ltd.), DMEM:Ham's F12 Mixed Medium (1:1) (e.g., Dainippon Pharmaceutical Co., Ltd.), Ham's F12 Medium (e.g., Dainippon Pharmaceutical Co., Ltd.), MCDB201 Medium (Research Institute for the Functional Peptides Co., Ltd.), or similar mediums may be used. A medium with added serum (e.g., bovine fetal serum, human serum, sheep serum, or similar) or a serum substitute (e.g., Knockout Serum Replacement (KSR) or similar) may also be used. The amount of serum or serum substitute added can be specified, for example, within a range of 5 to 30% (v / v). The process described above leads to the selective survival, selection, and proliferation of adherent cells. The proliferating cells are then collected. Collection can be done using only a conventional method; for example, cells treated with an enzyme (such as trypsin or despase) can be easily collected by separating them using a cell scraper, pipette, or similar device. Additionally, when culture substrates are prepared using a commercially available heat-sensitive culture dish or similar device, cells can also be collected as a wafer without enzymatic treatment. Using cells collected in this way allows for the preparation of a cell pool containing high-purity ADSCs. Low-serum culture (selective culture in low-serum medium) and cell collection In one embodiment of the present invention, the following low-serum culture is performed instead of or after procedure (3). The cells obtained in this manner are then used in the present invention as adipose-derived mesenchymal stem cells (ADSCs). In low-serum culture, the SVF fraction (and when this step is performed after procedure (3), the cells collected in procedure (3)) are cultured under low-serum conditions for the selective proliferation of the desired pluripotent stem cells (i.e., ADSCs). The low-serum culture method requires only a small amount of serum; therefore, when ADSCs obtained in the subject matter of the present invention are used for therapeutic purposes, the serum of the person being treated (the patient) can be used. That is, it becomes possible to culture using autologous serum. In this context, "low-serum conditions" means conditions in which the culture medium contains 5% (v / v) or less of serum. It is preferable to culture the cells in a culture solution containing 2% (v / v) or less of serum.Ideally, cells are cultured in a culture solution containing 2% (v / v) or less of serum and 1 to 100 ng / ml of fibroblast growth factor-2 (bFGF). A serum-free medium can also be used. The serum is not limited to bovine fetal serum; human serum, sheep serum, or similar serums may be used. When activated sperm obtained by the method described in the present invention is used to treat humans, human serum is preferred, and even more preferably, the serum of the person being treated (i.e., autologous serum). For the culture medium, a standard culture medium for animal cells may be used, provided that the amount of serum present at the time of use is low. For example, Dulbecco's Modified Eagle's Medium (DMEM) (such as NISSUI PHARMACEUTICAL CO., LTD. products), α-MEM (such as Dainippon Pharmaceutical Co., Ltd. products), DMEM:Ham's F12 Mixed Medium (1:1) (such as Dainippon Pharmaceutical Co., Ltd. products), Ham's F12 Medium (such as Dainippon Pharmaceutical Co., Ltd. products), MCDB201 Medium (Research Institute for the Functional Peptides Co., Ltd.), or similar can be used. The culture method described above allows for the selective proliferation of ADSCs. Furthermore, ADSCs cultured under the aforementioned conditions exhibit high proliferative activity, and thus the required cell count for the present invention can be readily prepared by secondary culture. International Publication WO2006 / 006692 A1 reveals the characteristics of cells that proliferate selectively when cultured with an SVF fraction under low-serum conditions. Subsequently, the cells that proliferated selectively by the low-serum culture described above are collected. The collection process requires only that it be carried out in the same manner as in Case (3) above. The use of the collected ADSCs allows for the acquisition of a cell pool containing ADSCs of high purity. In the method described above, cells proliferating from the culture of an SVF fraction in a low-serum medium are used. However, cells proliferating from the culture of a cell pool obtained from adipose tissue directly in a low-serum medium (without centrifugation to obtain an SVF fraction) can also be used as ADSCs. That is, in one embodiment of the present invention, cells proliferating from the culture of a cell pool obtained from adipose tissue in a low-serum medium are used as ADSCs. Furthermore, instead of pluripotent stem cells obtained by selective culture (processes (3) and (4) mentioned above), an SVF fraction (containing adipose-derived mesenchymal stem cells) can be used as is. "Use as is" in this context means its use in the present invention without undergoing selective culture. <Method for preparing a solution containing exosomes> (Step (1): Disabling ADSCs) To inactivate ADSCs, common cell inactivation methods can be used. For example, freeze-thaw treatment (freeze-to-thaw), ultrasound, French press, mortar, homogenizer, glass beads, or similar methods can be employed. Furthermore, cells subjected to inactivation treatment are not limited to live cells; dead or damaged cells can also be used. Of the inactivation methods mentioned above, freeze-thaw and ultrasound are preferred. In particular, freeze-thaw treatment is preferred due to its simplicity, its ability to avoid contamination from device-cell contact, and its hygienic nature. The preferred conditions for freeze-thaw inactivation will be described later.In the case of ultrasonic cell denaturation, it is preferable to perform the denaturation process using freshly frozen cells. It is also recommended to repeat the process for short periods while cooling the cell suspension on ice, since protein denaturation and aggregation often occur due to the heat generated by the device. Specifically, it is preferable to repeat the denaturation process for 5 to 15 seconds, followed by a 10 to 30-second pause, at an output power of 200 to 300 watts, several times. It is worth noting that repeated freeze-thaw cycles are preferred to ensure adequate cell thawing. This is because cells expand during freezing, forming ice crystals. These ice crystals then rupture the cells, causing them to thaw during the thawing process. Specifically, 1 to 5 freeze-thaw cycles are preferred, with 2 to 4 cycles being the most desirable. Examples of freezing methods include freezers, deep freezers, and liquid nitrogen. The freezing temperature in freeze-thaw cycles is not particularly specific, as long as it is a temperature at which the entire cell population can be frozen. The preferred range is -20°C to -196°C. More specifically, the upper limit of the freezing temperature is preferred at -20°C or lower, more preferable at -30°C or lower, and even more preferable at -70°C or lower. There is no specific cooling time requirement as long as it allows for the complete freezing of the cell pool. If using a freezer, it is preferable to place the cells in the freezer for one hour or more, ideally 10 hours or more, to ensure adequate cooling. There is no specific upper limit for cooling time, but 72 hours or less is preferable, 48 hours or less is even better, and 12 hours or less is even better. Ideally, the cell pool should be placed in a refrigerator or freezer before leaving the workplace, cooled overnight, and then work can resume the following day. When using liquid nitrogen, the container holding the cells can be stored directly, or the cells can be placed in a freezer container, which is then immersed in liquid nitrogen for cooling. Frozen cells can be thawed by any suitable method. For example, frozen cells can be placed in a water bath, incubator, refrigerator, thermostatic bath, or similar environment at a temperature higher than the freezing point. Specifically, thawing can be achieved by overnight incubation at 5°C or lower, double water bath thawing (e.g., 35–40°C), room temperature thawing, or similar methods. The concentrations of cell suspensions used for inactivation are preferred in the range of 1 × 10⁴ to 1 × 10⁸ cells / ml of ADSCs. Concentrations are more favorable in the range of 10 × 10⁴ to 1000 × 10⁴ cells / ml, and even more favorable in the range of 10 × 10⁴ to 500 × 10⁴ cells / ml of ADSCs. This concentration is easy to handle in practice, and it allows for obtaining a sufficient quantity of solution containing exosomes through a single process. (Step (2): Stirring the solution resulting from the inactivation) The inactivated solution is placed in a container such as a test tube and stirred using a stirrer or a vortex mixer. When using a stirrer, subsequent processes such as cleaning the stirrer motor are required, raising concerns about exosome loss due to the adhesion of the inactivated solution to the stirrer. Therefore, to increase production efficiency, stirring with a vortex mixer is preferred. For a solution with a high exosome concentration, the vortex mixer speed should ideally be between 100 and 3,500 rpm, with 1,500 to 2,700 rpm being the optimal range. The stirring time should ideally be between 1 and 30 minutes, with 3 to 25 minutes being the optimal range. For high exosome concentrations, short-time stirring is preferred, ideally between 1 second and 2 minutes. It is assumed that by creating a swirling motion at the bottom of the vessel and stirring it at high speed using a swirling mixer, exosomes can be efficiently extracted from the inactivated cells, resulting in a solution containing high concentrations of exosomes. The temperature during the stirring process is not particularly specific. The solution resulting from the inactivation process after stirring can be centrifuged, and the supernatant can be used in the subsequent step (filtration treatment). Centrifuging the inactivated solution after stirring removes nuclei and similar particles from the supernatant, preventing filter blockage and thus enabling efficient filtration. If centrifugation is performed, it is preferable to use a centrifuge of 100 to 1,500 × g for 3 to 10 minutes. The temperature during centrifugation is not particularly specific. (Step (3): Filtration step of the solution resulting from the inactivation after the stirring treatment or the supernatant after the centrifugation treatment) The solution resulting from the inactivation process after stirring, or the supernatant produced by centrifugation, is filtered through a filter. Unnecessary components can be removed by filter filtration. Furthermore, when using a filter with an appropriate pore size, removal of unnecessary components and sterile filtration can be performed simultaneously. The type of filter material used in the filtration process is not particularly specified, but cellulose acetate, which is less susceptible to protein adsorption, is preferred, as are metal filters. Cellulose acetate is especially favored. The filter pore size should ideally be between 0.1 and 0.45 µm, and even more so between 0.15 and 0.3 µm. When performing sterile filtration concurrently, a pore size of 0.2 µm is preferred. In this invention, “filter filtration” refers to a physical separation method for removing unnecessary components using the force of gravity.The basis of this method, as well as the components separated in it, differ from the basis of centrifugal separation, in which the precipitate and supernatant are separated using centrifugal force, centrifugal acceleration, viscosity, density differences between particles and liquid, etc. When the filtrate is not used directly for therapeutic purposes, it can be frozen until needed. Storage is best at temperatures between -100°C and -60°C. Generally, repeated freezing and thawing of cells tends to decrease cell viability and increase the number of dead cells. However, the solution containing exosomes according to this invention does not contain stem cells, and therefore its quality remains unchanged even after repeated freezing and thawing. In the exosome-containing solution described in the present invention, the solution itself can be used as a raw material without separating the exosomes, or the exosomes can be separated and used. The method for separating the exosomes from the exosome-containing solution described in this invention is not particularly specified; for example, the exosomes can be separated using methods such as filter filtration, gel chromatography, electrophoresis, or a combination thereof. Although the apparatus is expensive, the exosomes can be separated from the exosome-containing solution using a high-speed centrifuge. It can be confirmed that the exosomes obtained in this invention are the target exosomes by morphological observation using a transmission electron microscope, genetic analysis using PCR, immunological techniques (such as ELISA, FACS, or similar), Western blot, or other methods. <Solution containing exosomes according to the present invention> The solution containing the exosomes, as described in the present invention, should ideally contain exosomes at a concentration of 10 to 10,000 pg / mL, preferably 50 to 7,500 pg / mL, when measured based on the amount of CD63 protein using a CD9 × CD63 ELISA kit for human-derived exosomes manufactured by Cosmo Bio Inc., using a 1 × 10⁶ cell / mL cell suspension. A concentration between 75 and 5,000 pg / mL is preferable, and ideally, a concentration between 100 and 3,000 pg / mL. According to the production method described in the present invention, in addition to extracting extracellular exosomes, intracellular exosomes can also be extracted with high efficiency. Consequently, a solution containing high concentrations of exosomes can be produced. Furthermore, expensive equipment such as ultracentrifuges is not required, and the operating procedures are very simple, thus reducing production costs. Furthermore, the exosome-containing solution described in the present invention does not contain live cells, thus reducing the risks associated with live cells, such as carcinogenesis, and eliminating the problem of transplant rejection. There is also no risk of microvascular occlusion when the exosome-containing solution is administered as a medicinal preparation. Its preparation and handling are also straightforward, and it allows for long-term storage via freezing. Moreover, the exosome-containing solution described in the present invention not only contains a large quantity of exosomes but also a significant amount of various growth factors and other intracellular substances. <Use of the exosome-containing solution in accordance with the present invention> The solution containing the exosomes, obtained by the production method described in the present invention, can be used in various applications such as pharmaceuticals, food supplements, cosmetics, and food, as will be described later. The solution can be used as is, or the exosomes can be separated from the solution and used separately. Furthermore, it can also be used in formulations by mixing the solution containing the exosomes with an excipient or similar substance. For example, when used as a pharmaceutical preparation, examples include pharmaceutical preparations containing exosomes obtained by the production method according to the present invention, or isolated exosomes, as the active ingredient. Exosomes contain intracellular components such as DNA, mRNA, miRNA, and protein, and are believed to have multiple physiological functions. In particular, the exosome-containing solution according to the present invention is effective in tissue regeneration, as it is assumed to contain not only a large quantity of exosomes but also a large quantity of various growth factors. Specifically, the solution containing exosomes can be used as a therapeutic preparation for the following diseases, for example: diseases of the central nervous system such as Alzheimer's disease, Parkinson's disease, and the aftermath of cerebral infarction; diseases of the respiratory system such as chronic obstructive pulmonary disease and chronic pulmonary embolism; diseases of the heart such as myocardial infarction and heart failure; diseases of the kidney such as nephritis (including chronic nephritis) and nephrotic syndrome; diseases of the pancreas such as diabetes and pancreatitis; inflammatory bowel diseases such as inflammatory bowel disease and Crohn's disease. In addition, it can be used as a therapeutic preparation for diseases in which skeletal and motor functions are affected, such as rheumatism, knee osteoarthritis, herniated discs, diseases in which maintaining body balance is difficult, and diseases in which a decrease in muscle strength is observed, such as amyotrophic lateral sclerosis.Furthermore, the solution containing the exosomes, according to the present invention, is supposed to exhibit several effects, including: significant amplification of cumulus cells, a dominant decrease in reactive oxygen species (ROS), improved distribution and function of mitochondria, a reduction in the rate of primary cell death in oocytes, improved conditions for nuclear maturation and in vitro fertilization, improved developmental capacity of in vitro fertilized oocytes, and improved embryo quality at the blastocyst stage. It is also said to improve sperm motility, and thus can be used to treat and improve infertility resulting from impaired oocyte and sperm function, low sperm count, endometriosis, and similar conditions, as well as to improve the success rate of in vitro fertilization, livestock breeding, and species conservation (such as the preservation of endangered species, the preservation of domestic breeds, or hybridization), etc.In addition, it is said that exosomes, due to their bilayer lipid structure, penetrate the dermis of the skin and induce skin regeneration and anti-aging factors by stimulating the proliferation and activation of fibroblasts, and promoting collagen synthesis, and thus can also be used in anti-aging and cosmetic applications. Alternatively, the exosomes can be incorporated into various tissues and are expected to have a restorative effect on tissues whose functions have deteriorated. Therefore, their use as an enhancer for restoring endurance and preventing fatigue is also effective. Fatigue causes a decrease in the efficiency of functional activity. Moreover, when fatigue continues to accumulate, it may be a contributing factor to the development of disease. Therefore, the pharmaceutical preparation of the present invention is also effective as a preventative agent against the onset of disease. Alternatively, the exosome-containing solution that is the subject of this invention is preferred for use as a dietary supplement for non-human mammals, with the exosome-containing solution as the active ingredient. In this context, a dietary supplement is defined as a nutrient-rich source or other substance with a nutritional or physiological effect intended to supplement a normal diet and perform a beneficial function in maintaining health and recovering from fatigue. A pharmaceutical preparation containing the solution with the exosomes as the active ingredient may include an acceptable and non-toxic pharmaceutical excipient, such as a solid, semi-solid, or liquid diluent, dispersant, filler, or carrier. Furthermore, provided the effect of the present invention is not diminished, substances such as a stabilizer, preservative, pH regulator, binder, solvent, surfactant, lubricant, flow accelerator, flavoring agent, coloring agent, aromatic preservative, antimicrobial agent, medium, physiological saline, antibacterial agent, or a drug with another medicinal effect may be added. Of these components, it is preferable that a medicinal preparation containing an exosome-based solution as an active ingredient also contains an antibacterial agent. An antibacterial agent is defined as a compound or similar substance exhibiting antibacterial activity, such as antibiotic and antifungal solutions, isopropyl methylphenol, clove oil, thymol, chlorhexidine hydrochloride, and cetylpyridinium chloride. It is preferable that these substances be present in sufficient quantities to demonstrate the antibacterial activity. The inclusion of an antibacterial agent in the medicinal preparation that is the subject of this invention inhibits the growth of pathogenic bacteria, thereby ensuring the safety of the preparation for a specified storage period. The form of the medicine containing the solution with the exosomes as the active ingredient, which is the subject of the present invention, is not specifically limited. It may be liquid or solid, and may be frozen and / or dried to be manufactured as a powder. It may be formulated in various forms depending on the intended use. The dosage form may be powder, granules, tablets, capsules, injection, infusion, inhalation, ointment, eye drops, nasal drops, or a substance for transdermal absorption. The method of administration of the drug containing the exosome solution as the active ingredient, which is the subject of the present invention, is not particularly limited and may be by local or systemic administration. Examples include subcutaneous injection, intradermal injection, intramuscular injection, intralymphatic injection, intravenous injection, arterial injection, intraperitoneal injection, intrapleural injection, direct local injection, or direct application. In the case of intravenous injection in particular, the drug is distributed directly throughout the body via the bloodstream, resulting in a high blood concentration. Therefore, when an immediate effect is required, intravenous administration of the drug containing the exosome solution as the active ingredient is preferred. Any dose of the drug containing the exosome solution as the active ingredient may be used, provided it achieves a therapeutic effect and an effective amount is administered. The level depends on the type of solid, the severity of the condition, the patient's age, sex, and the type of disease, among other factors. The frequency of administration depends on achieving a therapeutic effect when the drug is administered according to the present invention. Similarly, the duration of administration is such that the therapeutic effect is achieved when the drug is administered according to the present invention. The intended recipients of this invention are humans and non-human mammals for whom treatment is desired or sought. Non-human mammals include, for example, monkeys, pigs, cows, horses, goats, sheep, dogs, cats, camels, mice, rats, guinea pigs, hamsters, etc., and include pets, livestock, and laboratory animals. [Examples] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples at all. (1) Preparation of a solution containing exosomes <Preparation 1 of the filtrate solution resulting from the inactivation of fat-derived stem cells (freeze-thaw)> The filtrate solution was prepared as described here using human adipose stem cells (person A). Specifically, ADSCs were propagated by culture of human adipose stem cells in MesenPRO RS Medium. Secondary culture of 6 cells was performed with the medium changed every two days until 5 × 10⁶ cells were obtained. A concentration was prepared using PBS to create a cell suspension with a concentration of 1 × 10⁶ cells / ml. This was then frozen in a freezer at -20°C for 1 day and in a deep freezer at -80°C for 12 hours. Instant freezing is possible using liquid nitrogen (-196°C), but here the container with the cell suspension was immersed in liquid nitrogen for 30 minutes before measurement. The frozen cell suspension was then placed in a refrigerator at 4°C and thawed until complete thawing was visually confirmed. The cells were thus inactivated and then subjected to agitation using a vortex mixer for the time specified in Table 1. The rotation speed was 2,500 rpm. The resulting liquid was then filtered through a cellulose acetate membrane filter (pore size: 0.2 μm) to obtain an exosome-containing solution. Serum-free medium (KBM ADSC-5, Kohjin Bio Co., Ltd.) was used as a control. Quantitative analysis of exosomes by ELISA The amount of exosomes in the solution containing the exosomes prepared above, the culture supernatant, and the serum-free medium was measured as CD63 protein using the CD9 × CD63 ELISA kit for measuring human-derived exosomes manufactured by Cosmo Bio Co., Ltd. The measurement method was followed according to the kit manufacturer's protocol. The results are shown in Table 1 and Figure 1. Figure 1 is a graph of the results in Table 1. As can be seen from Table 1 and Figure 1, the solution containing exosomes, produced by stirring the frozen-thawed sample with a vortex mixer and filtering the mixture through a filter, contained exosomes at a high concentration. The effect was more pronounced as the freezing temperature decreased. In particular, Example 3-3 contained approximately 30 times more exosomes than the control (the culture supernatant). As mentioned above, the production method described in the present invention can easily produce a solution containing exosomes at high concentrations and in large quantities. The exosomes are expected to have various applications. [Table 1] Sample name, freezing conditions, conditions of presence and absence of vortex, amount of oxosomes contained in the oxosome-containing solution (picogram / mL) Example 1-1 Example 1-2 Example 1-3 Frozen Frozen Frozen - 5 min 20 min 26.8 70.1 79.1 Example 2-1 Example 2-2 Example 2-3 Deep Freezer Deep Freezer Deep Freezer - 5 min 20 min 35.1 168.1 160.1 Example 3-1 Example 3-2 Example 3-3 Liquid Nitrogen Liquid Nitrogen Liquid Nitrogen - 5 min 20 min 50.2 198.1 237.7 Two-day culture of CMS PBS medium - - - - - - 8.3 - - <Second preparation of the solution resulting from the inactivation of stem cells derived from adipose tissue (freeze-thaw)> Human adipose tissue-derived stem cells (human B cells) were cultured in MesenPRO RS Medium for the proliferation of adenocarcinoma stem cells (ADSCs). Six cell subcultures were performed, with the medium changed every two days, until 5 × 10⁶ cells were obtained. The concentration was then prepared using PBS to generate a cell suspension with a concentration of 1 × 10⁶ cells / ml. The same procedure described in the initial preparation of the solution resulting from the inactivation of adipose tissue-derived stem cells (freeze-thaw) was then performed, but with varying operating conditions (freezing conditions, number of freeze-thaw cycles, and stirring time using a vortex mixer). The operating conditions and results are shown in Table 2. Reducing the stirring time to one minute or less resulted in a solution containing higher concentrations of exosomes. It can be argued that a shorter stirring time is preferable due to its ease of operation and excellent efficiency. [Table 2] Sample name, freezing conditions, number of freeze-thaw cycles (cycles), vortex time, amount of oxosomes contained in the oxosome-containing solution (picograms / mL) Example 4-1 Example 4-2 Example 4-3 -20°C -20°C -20°C 3 3 3 5 seconds 10 seconds 30 seconds 1748.4 2097.9 2208.9 Example 4-4 Example 4-5 Example 4-6 -20°C -20°C -20°C 3 3 3 1 min 5 min 10 min 2105.9 1741.9 1492.4 Example 5-1 Example 5-2 Example 5-3 -80°C -80°C -80°C 3 3 3 5 s 10 s 30 s 2170.9 2178.9 2410.9 Example 5-4 Example 5-5 Example 5-6 -80°C -80°C -80°C 3 3 3 1 min 5 min 10 min 2015.4 1810.4 1315.9 Example 6-1 Example 6-2 Example 6-3 -196°C -196°C -196°C 3 3 3 5 seconds 10 seconds 30 seconds 2455.4 2485.9 2544.9 Example 6-4 Example 6-5 Example 6-6 -196°C -196°C -196°C 3 3 3 1 minute 5 minute 10 minute 2320.4 1828.9 1151.9 Evaluation of the solution containing exosomes in dogs (its effect on chronic nephritis) An exosome-containing solution was prepared using mesenchymal stem cells from a 3-year-old male beagle using the same method as for human adipose tissue-derived stem cells. The following canine cells were used: • Receive combined vaccinations, filariasis prevention, and rabies prevention annually; • Not having received any blood transfusions previously; • Absence of systemic infectious skin diseases; • Not suffering from any bloodborne infection, such as babesiosis or canine brucellosis, and not suspecting infection with them so far; • Absence of acute metabolic or endocrine diseases; • Not suffering from any hereditary disease; and • Not suffering from malignant tumors. Canine ADSCs meeting the above criteria were collected, multiplied, and secondary cultured 6 times to prepare a cell suspension with a concentration of 1 × 10⁶ cells / ml. The suspension was frozen in a deep freezer at -80°C for 12 hours. The frozen cell suspension was then placed in a refrigerator at 4°C and thawed until thawing was visually confirmed. This process was then repeated. Stirring was performed at 2,500 rpm for 5 minutes using a vortex mixer, and the resulting agitation-treated liquid was filtered through a 0.2 μm cellulose acetate filter to obtain a canine exosome-containing solution. A female dog with chronic nephritis (Meinier Daxhand, 18 years old) was injected intravenously with the exosome-containing solution described above (prescribed for dogs), approximately every two months, for a total of four injections. As a result, as shown in Table 3, a decrease in urinary creatinine and urea nitrogen (BUN) values was confirmed after administration of the exosome solution according to the present invention. Creatinine and BUN concentrations were measured using a FUJI DRI-CHEM NX700V animal clinical chemistry analyzer. [Table 3] Blood Chemistry Tests Reference Standard Value 2023 / 04 / 28 (Before administration) 2023 / 12 / 30 (After administration four times) BUN (Urea Nitrogen) 9.2 to 29.2 (dL / mg) 57.6 45.2 Creatinine (0.40 to 1.40 dL / mg) 2.17 0.60 Evaluation of the solution containing exosomes in dogs (its effect on hernias) A herniated disc is a condition in which the cartilage (intervertebral disc) that cushions the vertebrae in the lower spine deteriorates, causing a portion of the tissue to protrude. This can lead to lower back pain, numbness, or pain in the buttocks or feet. In dogs, a herniated disc may present with symptoms such as unsteady gait, inversion of the rump, and difficulty rising as paralysis increases. In this study, a canine exosome solution was administered intravenously every two weeks, for a total of four injections, to both a Pomeranian (whose lumbar herniated disc had been present for approximately one year) and a Meanie Daxhand (whose herniated disc had been present for approximately three years). As a result of monitoring the dogs' condition before and after administration of the exosome-containing solution according to the present invention, improved gait, pain relief, and increased activity (energy) were confirmed, as shown in Table 4. The assessment in Table 4 illustrates the animals' conditions and activities as determined by the observer (the observer and / or the therapist) through direct observation. A quality-of-life scale known as the HHHHHMM scale was also used to evaluate the outcomes. [Table 4] Pomeranian (male / 6 years old) Meenie Daxend (female 12 years old) Before giving, after giving, before giving, after giving Characteristics of walking difficulty: Difficulty walking × jumping; difficulty walking or a decrease in movement speed in the waist and sides (disruption of gait pattern); smooth walking without stumbling and improved jumping power with a clear improvement in gait pattern. Presence or absence of pain: Presence of pain (screams when held) No pain (does not scream even when held) Presence of pain (screams and bends backwards when held) No pain (does not scream or bend even when held) Activity (vitality): Lethargic (no movement, little interaction with owner); Loss of vitality; Improvement in vitality (moves well) Symptoms of diarrhea - Diarrhea symptoms without symptoms - Improvement of diarrhea symptoms Quality of life (HHHHHMM S HURT5 HURT0 HURT6 HURT1 scale) (4) Evaluation of the solution containing exosomes in dogs (activity improvement effect) A female beagle (aged 12 to 13 years) suffering from the following symptoms was injected intravenously with the exosome-containing solution (intended for dogs) once every two weeks, for a total of four times. As a result of monitoring the dog's condition before and after administration of the solution containing the exosomes that are the subject of this invention, an improvement in walking ability and activity level (vitality) was observed, as shown in Table 5. Similar to Table 4, this assessment represents the animal's condition and activity level as determined by the observer (the observer and / or the therapist) through direct observation of the animal. This improvement is presumed to be due to the exosomes' effect in removing reactive oxygen species and their effect in inhibiting inflammation and pain at the cellular level. [Table 5] Condition before administration Condition after administration (Diagnosis outcome unknown) (5) Evaluation of the solution containing exosomes in horses The effect of the exosome-containing solution on horses was also evaluated. The exosome-containing solution used in this evaluation was prepared in the same manner as the one used in the canine test described above, except that a 5 × 10⁶ cell / ml cell suspension was used. Racehorses were injected intravenously with 1 ml of the exosome-containing solution, and their condition was assessed one week after administration. The assessment was performed by a veterinarian, according to the following criteria. [Table 6] Assessment criteria: hair shine, muscle tension (stiffness), mood 1. Very bad, extremely bad mood 2. Very weak, extremely weak, extremely bad mood 3 Bad, bad, bad mood 4. Slightly bad, slightly bad mood 5 Natural Natural Natural 6. Slightly suitable. Slightly suitable. Slightly quiet. 7 Suitable, quiet 8. Perfectly fit, perfectly fit, perfectly quiet 9. Very suitable, extremely quiet The evaluation results are presented in Table 7. These results also demonstrate that administering the exosome-containing solution according to the present invention has a positive effect on the horses' physical condition and psychological well-being. Racehorses are subjected to considerable stress due to transportation, training, and participation in races, and this stress is often reflected in their coat shine, muscle tone, temperament, and other characteristics. However, when the exosome-containing solution of the present invention was administered, a significant improvement in physical condition and a marked improvement in temperament were observed in the horses. [Table 7] Hair shine before administration - after administration; muscle tension (stiffness) before administration - after administration; mood before administration - after administration Horsepower 1 5 → 9 5 → 9 5 → 8 2 horsepower → 9 5 → 9 5 → 9 3.5 horsepower → 8.5 horsepower → 9.5 horsepower → 7 horsepower 4 horsepower → 9 5 → 9 5 → 9 Horse 5 5 → 9 5 → 9 5 → 9 6.5 horsepower → 8.5 horsepower → 8.5 horsepower → 9 horsepower Industrial applicability The production method described in the present invention can readily produce a solution containing exosomes at a high concentration and in large quantities. Furthermore, a pharmaceutical preparation or supplement containing the exosome-containing solution described in the present invention as an active ingredient exhibits a fatigue recovery promoter effect.
Claims
1. A method for producing an exosome-containing solution derived from mesenchymal stem cells. This method includes: (1) inactivation of the mesenchymal stem cells; (2) stirring the solution resulting from the inactivation obtained in step (1) using a stirrer or vortex mixer; and (3) filtration of the solution resulting from the inactivation after stirring, by passing it through a filter.
2. A method for producing an exosome-containing solution according to protection element 1, where the mesenchymal stem cells are mesenchymal stem cells derived from adipose tissue.
3. A method for producing an exosome-containing solution according to protection element 1 or 2, where step (1) is performed by freeze-thaw or using ultrasonic waves.
4. A method for producing an exosome-containing solution according to protection factor 1 or 2, where the solution resulting from inactivation in step (2) is stirred using a vortex mixer at a speed of 100 to 3,500 rpm for a duration of 1 to 30 minutes.
5. A pharmaceutical preparation containing, as an active ingredient, the exosome-containing solution produced according to protection factor 1 or 2.
6. A fatigue recovery agent, where the pharmaceutical preparation according to protection factor 5 is administered intravenously.
7. A dietary supplement for non-human mammals containing, as an active ingredient, the exosome-containing solution produced according to protection factor 1 or 2.
